https://www.oncotarget.com/article/11163/text/
Preclinical activity of melflufen J1 in ovarian cancer | Oncotarget
https://doi.org/10.18632/oncotarget.11163 Charlotte Carlier, Sara Strese, Kristina Viktorsson, Ebba Velander, Peter Nygren, Maria Uustalu, Therese Juntti, Rolf...
ovarian cancerpreclinicalactivitymelflufenoncotarget
https://bpno.no/artikler/melflufen-is-safe-and-effective-in-patients-with-alkylator-refractory-disease/
Melflufen Is Safe and Effective in Patients with Alkylator-Refractory Disease
May 22, 2024 - Fredrik Schjesvold gives his insights into the OCEAN trial, which investigates melflufen's role in refractory multiple myeloma by comparing...
safe and effectivein patientsmelflufen
https://multiplemyelomahub.com/therapeutics/peptide-drug-conjugates/melflufen
Multiple Myeloma Hub | therapeutics / peptide-drug-conjugates / melflufen
peptide-drug-conjugates of therapeutics of melflufen
multiple myelomadrug conjugateshubtherapeuticspeptide
https://oncopeptides.com/press-releases/oncopeptides-ab-data-from-oncopeptides-clinical-trials-horizon-and-anchor-evaluating-melflufen-in-rrmm-selected-for-presentation-at-the-aacr-annual-meeting/
Oncopeptides AB: Data from Oncopeptides Clinical Trials HORIZON and ANCHOR Evaluating Melflufen in...
Stockholm - 27 February 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that data from its Phase II HORIZON study and Phase I/II ANCHOR study
clinical trials